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Abstract

Introduction

Due to different functional demands and vascularity,
the mandibular and craniofacial complex require bone
regenerating materials with physical and chemical properties that are different from long bone. However,
certain common requirements to both locales must be
addressed. Furthermore, reasons why the autograft and
allogeneic bank bones are successful in regenerating
bone need to be understood if the researcher is to
develop satisfactory alternatives. The purpose of this
paper is to review some of the requirements needed for
bone regenerating materials for mandibular and craniofacial bone repair. In that effort, we have briefly
described the autograft and allogeneic bank bones, animal wound models, quantitative assays, certain bone regenerating factors (growth factors and bone inductive
proteins), and requirements of delivery systems for presenting bone regenerating factors to the osseous host
bed.

The autogenous graft is the most frequently used
material for regenerating deficient bone in the mandibular and craniofacial complex; while allogeneic bank
bone is the second most commonly used material. N either the autogenous graft nor the allogeneic bank bone
provide the patient with ideal results. Both modes of
treatment have a sufficient number of deficiencies that
warrant searching for superior alternatives. Over the
millennia, there have been a diverse and sometimes curious selection of materials that surgeons have implanted
into their patients. In an effort to either regenerate or
replace deficient bone, metal and alloys (gold, steel, titanium) and semi-precious gems have been used; various
animal products (whole or anorganic dog and cow bone;
collagen) and ceramics (different stoichiometries of calcium-phosphates, calcium-carbonates, and calcium-sulfates) have been tried; and many types of partially purified proteins and recombinant proteins have been examined (demineraliz.ed bone matrix; antigen extracted,
allogeneic bone; bone morphogenetic proteins). At this
time, the autogenous graft and allogeneic bank bone are
the most effective substances for regenerating new bone.
If researchers are to develop alternatives to the autogenous graft and allogeneic bank bone, it is important to
study and to understand the biochemical and cellular
mechanisms governing fracture repair and regeneration
of ablative osseous wounds. Mol'.eover, it is singularly
important to understand why the autograft, despite recogniz.ed deficiencies, promotes bone regeneration to a
degree that cannot be matched by any man-made material. If researchers are to be successful in developing
alternatives, not only must they be mindful of complex
biochemical and cellular processes promoting bone regeneration, they must evaluate potential alternatives in a
hierarchy of defined animal wound models using quantitative methodology. The purpose of this paper, therefore, is to review some concepts governing bone wound
repair and to highlight potential laboratory synthesiz.ed
agents that may be available to surgeons as alternatives
to the autograft and allogeneic bank bone. Furthermore,
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cells contribute to neovascularization (Marks, 1986).
Macrophages and monocytes release the cytokine interleukin-1 (IL-1). As yet the roles of IL-1 have not been
completely determined; however, it is associated with
mitogenesis of certain bone marrow cells and osteoclasts. Friedenstein described two types of osteogenic
cells based on their functional properties: determined
osteoprogenitor cells (DOPC) and inducible osteoprogenitor cells (IOPC; Friedenstein, 1973). Purportedly,
DOPC are derived from pluripotential cells in the
periosteum and marrow, whereas IOPC are derived from
mesenchymal precursors that are induced to express
specific phenotypes based on the inducting agent
(morphogen).
The biochemical signals that herald the appearance
of chondrocytes and osteoblasts remain to be elucidated.
However, it is likely that proteins and polypeptides (i.e.,
bone morphogenetic protein, interleukins, growth factors) are released from endogenous depots, such as fracture ends and from the hematoma. While bone morphogenetic protein (BMP) has been directly implicated in
bone induction, it has not been identified at the fracture
callus (Brighton, 1984). Fractures bring about the release of prostaglandin £i (PG£i) from the bone and
muscle. While PG£i has osteolytic effects in vitro,
there is putative evidence that effects in vivo promote
bone formation (Chapman, 1987). It is likely that
growth factors regulate both bone resorption and formation (remodeling). At the fracture site, transforming
growth factor beta (TGF-/3) is released in a latent form
that is activated by proteolytic enzymes. In its activated
form, TGF-/3 promotes conversion of mesenchymal cells
into cartilage cells and it enhances production of collagen, fibronectin, and plasminogen activating factor in
osteoblasts. Additional comments on TGF-/3 will be
made later in this paper.
The embryologic origin of bone was thought to have
a lasting and significant impact on the sequence of fracture healing. Endochondrally derived long bone repairs
fractures through a cartilaginous process, whereas intramembranous bone fractures lack a cartilaginous phase.
The literature taught that maxillary fractures did not heal
by osseous union because the maxilla lacks a periosteum
(Brayshaw, 1947). However, there have been animal
studies refuting this clinically derived assumption and a
recent human study has dispelled the notion of fibrous
healing of the mid-face fracture (Thaller and Kawamoto,
1990).
Regulatory chemical messengers of fracture repair
can be classified as autocrine (the synthesis and target
cells are one in the same), paracrine (the synthesis cell
product diffuses to a different responding cell), and
endocrine (the synthesis product transits via the blood
from source cell to target cell; Sporn and Todaro,

this discourse will point out an animal paradigm and the
quantitative methodology that we use in our laboratory
for evaluating bone regeneration materials for the
mandible and craniofacial complex.

Review
Fracture Repair
As a consequence of fracture, a hematoma results
from bleeding within bone marrow, cortical blood supply, periosteal envelopes, and soft tissues (McKibbon,
1968). The hematoma is the first stage of fracture healing. Concurrent with the fracture hematoma is the inflammatory response. Local cell proliferation begins by
day one and continues for about three days (Simmons,
1985). On the third day, mesenchymal cells condense
and by day five, cartilage formation takes place. At the
hematoma site, there is an abundance of class II histocompatibility cells with la molecules (i.e., in human:
HLA-DR; Hulth, 1989). It has been postulated that certain osteoregenerative molecules have beta-microglobulin
bound to the histocompatibility complex (Hulth, 1989).
Therefore, the presence of these immune complexes may
be a biochemical method for modulating bone induction.
Cells such as polymorphonuclear leukocytes, histiocytes,
lymphocytes, and mast cells migrate in time dependent
waves to remove necrotic debris while endothelial cells
proliferate and develop into capillaries penetrating the
fracture hematoma. Within the hematoma, degranulating
platelets (comprising the bulk of the hematoma) release
platelet derived growth factor and transforming growth
factors from their alpha granules. These polypeptides
are chemoattractants and mitogens that have their initial
effect on prefibroblast cell types. Fibroblast phenotypes
elaborate a meshwork of loose connective tissue that
contains proliferating capillary buds referred to as granulation tissue. The acidic pH and low oxygen tension
within the hematoma result in the development of chondroblastic cells that elaborate hyalin cartilage which
calcifies. As the vascular healing response matures and
the oxygen tension increases to approximately 200 mm
Hg, calcified cartilage is degraded and the healing fracture becomes replaced by pre-osteoblasts that differentiate into osteoblasts. The osteoblast cell line is thought
to develop from pericytes found in the invading vascular
tree (Owen, 1980). Fracture repair, therefore, proceeds
in a centripetal direction through the hematoma, developing a bone-like callus that has a contour of greater
mass and size than the original bone. By the process of
remodeling, the original bony contour is returned.
Within the first seven days of its development, fracture
callus contains a high concentration ofhyaluronate which
is associated with the promotion of cell migration and
mitogenesis of mesenchymal and endothelial cells. Mast
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1980). Transforming growth factor beta (TGF-Jj) is
both an autocrine and paracrine cell modulator. Macrophages release TGF-Jj which affects fibroblasts and endothelial cells. Insulin-like growth factors 1 and 2 (IGF1 and 2) are examples of endocrine cell modulators.
The cell modulators (chemical messengers) are peptide
to polypeptide sized moieties whose primary attributes
are to promote chemoattraction and mitogenesis. The
regulatory chemical messengers associated with callus
formation at the fracture are platelet derived growth factor (PDGF) (mitogenic for fibroblasts and bone cells; activates monocytes and promotes bone resorption); epidermal growth factor (EGF) (mitogenic for
chondroblasts and osteoblasts; inhibitory for type I bone
collagen, and promotes bone resorption); fibroblast
growth factor (FGF) (mitogenic for fibroblasts,
chondroblasts and osteoblasts); TGF-Jj (a mitogen to
osteoblasts and augments collagen synthesis); IGF
(enhances chondrocyte proliferation, proteoglycan
synthesis and collagen synthesis); nerve growth factor
(NGF) (a differentiation maintenance factor); and the
monocytic interleukins (IL-1, a potent bone resorption
factor, which enhances fibroblast proliferation,
collagenase and prostaglandin production; and IL-2,
which may enhance T -cell growth factor and aid in bone
resorption; Hauschka 1990). Despite the compelling
evidence for the action of the autocrine, paracrine, and
endocrine factors, one needs to be mindful that most
data are based on in vitro actions in isolated cell
preparations.
That growth factors are operant in
fracture healing and repair needs to be determined by
immunohistochemical and molecular biologic methods.
Moreover, strict attention needs to be paid to the biochemical-chronopharmacologic effects of the growth factors. Because of the importance of these chemical messengers, additional comments later in this paper will be
directed at their relevancy to bone regeneration.
Medullary callus repair studies indicate that capillary
and venous endothelial cells in the fracture region enlarge, polymorphic mesenchymal cells stream to the
fracture site and become abundant throughout the medullary callus, and osteoblasts and bone formation occurs
24 hours post-fracture (Heiple et al., 1987). There is a
suggestion that endothelial cells, reticular cells, blood
vessel pericytes, and polymorphic mesenchymal cells
may be interrelated and either may be osteoblast progenitor cells or may in some manner lead to phenotypic expression of osteoblasts.

ance of inflammatory exudate is typified by such cells as
lymphocytes, polymorphonuclear leukocytes (neutrophils), and plasma cells. Between 7-14 days, granulation tissue develops, giant cells and osteoclasts populate
the graft host bed, and angiogenesis commences. During the first 14 days, there is little difference between
the cancellous versus cortical autograft. Revascularization of the cancellous graft may occur within hours after
transplantation due to anastomoses with host and graft
vessels. In contrast, cortical grafts revascularize at a
slower pace. The cortical graft is eroded in a centripetal
fashion by the cutting cone of osteoclasts; therefore, by
14 days post-transplantation, the cortical graft is pockmarked with erosion channels. The ingress of cutting
cones begins to subside by six weeks; however, cortical
block grafts are weaker in physical properties than native bone. From the sixth week until six months, block
grafts may be 40 % to 50 % weaker than host bone
(Burchardt, 1987). By the first to second year after
transplantation, porosity diminishes and the graft may be
as strong as natural bone. The cortical graft may be admixed with host bone for the lifetime of the recipient,
whereas cancellous grafts are completely replaced by
regenerated host bone.
Autograft repair is in small part dependent upon the
contribution of transplanted osteoprogenitor cells. A
variable number of osteocytes survive the grafting procedure. Cells of the cambial layer of the periosteum can
convert to preosteoblasts under the influence of inductive
factors present in the graft and the host bone stump
ends. Moreover, endosteal and marrow cell elements
contribute inducible and determined cell populations that
develop into preosteoblasts phenotypes. As the graft
cells produce their protein products, bone regeneration
progresses in a centripetal direction through the graft.
Bone ingrowth into the graft is termed osteoconduction;
while the conversion of inducible cells into osteoblast
phenotypes is referred to as osteoinduction. The internal
architecture of the autograft affords appropriate spatial
dimensions to allow for neovascularization, cell anchorage, and proliferation to occur, thereby insuring for optimal osteoconduction and osteoinduction.

Bone Graft Repair: Allograft
In general, allografts are not incorporated as well in
the host bed as autografts. The differences in large part
are due to histocompatibility antigens derived from the
cell surface contaminants of the allograft. As a consequence of histoincompatibility, allografts may be completely rejected and resorbed at the host bed. The consequence is fibrous union and soft tissue prolapse rather
than bone regeneration. The modes of action of a successful allograft reside in the osteoconductive and osteoinductive principles. Allografts do not contribute a via-

Bone Graft Repair: Autograft
The cellular and biochemical events at the graft-host
interface are a reiteration of fracture repair. During the
first seven days, the hematoma and inflammatory response is characterized by vascular invasion, the appear-
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ble cell population for the development of osteoblasts.
Depending upon the degree of host acceptance of the
allograft, during the first two weeks there is a typical
inflammatory phase. This phase may be chronic, lasting
upwards of a year. While new bone formation may be
seen at the host margins of an autograft within a week
post-transplantation, there may be a delay with the allograft. If the allograft is accepted by the host, most all
phases of bone repair are substantially retarded as compared to the autograft (Burchardt, 1987).

and measure the biochemical, cellular, and stromal
events of the bone regeneration cascade. Our laboratory
strongly advocates applying modem, quantitative
methods to assessing bone regenerating materials.

Bone Regenerating Factors:
Demineraliud Bone Matrix, The Bone
Morphogenetic Proteins, Growth Factors
Preface
The major phases of new bone formation include
migration of progenitor cells, mitosis of mesenchymal
stem cells, differentiation to cartilage and bone, mineralization and remodeling, and hematopoietic marrow differentiation. The initiation of the bone formation cascade is triggered by a bone inductive protein(s) (Reddi
et al., 1988) and proliferation of progenitor cells is
modulated by a number of growth factors (Canalis et
al., 1988). Bioactive proteins such as bone morphogenetic proteins (BMP) induce the differentiation of pluripotential cells into cartilage-forming cells and boneforming cells (Urist, 1965). Several osteoinductive proteins (Sampath et al., 1987; Urist et al., 1984) and
growth factors (Hauschka et al., 1986) have been isolated from bone using different purification procedures.
Some have been found to have considerable amino acid
sequence homology. A number of growth factors involved in wound healing are believed to be relevant in
bone remodeling. These growth factors are surmised to
act in concert with osteoinductive protein, thereby augmenting osteanaphysis. Recently, a family of seven
BMPs has been cloned by recombinant DNA technology
and expressed. The members include BMP-1, BMP-2,
BMP-3 (osteogenin: OG), BMP-4, BMP-5, BMP-6, and
BMP-7 (osteogenic protein-1). The availability of recombinant BMPs will allow investigations of the mechanism of their actions and plausible clinical applications.
The following brief review examines bone derivatives,
inductive protein, and growth factors that may be
relevant for craniofacial bone regeneration.

Animal Paradigms Used to Stud_y Bone Regeneration
Materials
Alternatives to the graft and allogeneic bank bone
must be assessed in bony wounds that do not heal by
spontaneous bone formation. An intraosseous defect that
fulfills this criterion is known as a critical size defect
(CSD). If a bone regeneration material (BRM) is placed
into a CSD and the defect goes to bony union, the bony
union may be attributed to the capacity of the BRM to
initiate the cascade of chronobiological events at the
appropriate tempo to promote osteanaphysis. Our laboratory advocates a series of animal models for assessing
BRMs that include rats, rabbits, dogs, and non-human
primates (Hollinger and Kleinschmidt, 1990; Schmitz
and Hollinger, 1986). We emphasize the importance of
CSDs as a means to standardize comparisons of BRMs
between laboratories. Animal paradigms using intraosseous CSDs have been reviewed (Hollinger and
Kleinschmidt, 1990; Schmitz and Hollinger, 1986). It
is strongly suggested, therefore, these reviews be
consulted prior to embarking upon extensive BRM
studies.

Quantitative Methods to Evaluate Bone Regenerating
Materials
Quantitative evaluation of bone formation can be accomplished using computer imaging of histologic slides
and X-ray films. The beauty of quantitative histology
(histomorphometry) and quantitative radiology (radiomorphometry) is that the elements of bone formation can
be objectively tallied and reviewed in a manner that can
be reproduced by various laboratories. The scanning
electron microscope (SEM) with backscatter detection
has become an invaluable tool to bone researchers who
evaluate bone growth in ceramic materials. Likewise,
X-ray microanalysis and SEM can be applied to detection of bone formation across a CSD treated with bone
regeneration compounds. Both SEM with either X-ray
microanalysis or backscatter detection have been discussed in reviews and have been applied as research
tools to investigate bone regenerating agents (Hollinger
and Kleinschmidt, 1990). Biochemically, histochemically, immunohistochemically, and using in situ hybridization technology the modem bone researcher can evaluate

Demineraliud Bone Matrix
Repair of craniomaxillofacial osseous defects with
demineralized bone matrix (DBM) has been demonstrated (Glowacki et al., 1982; Mulliken, 1982). The
sequence of events of induced bone development was described by Urist using demineralized cortical block matrix (Urist, 1965; U~st et al., 1973). When DBM is implanted subcutaneously in allogeneic recipients, it releases factors which act as local mitogens to stimulate
proliferation of mesenchymal cells (Rath and Reddi,
1979). Mesenchymal cells differentiate by day five to
chondroblasts, to chondrocytes by day seven, and to osle()blasts by day eleven. The angiogenesis that ensues
b)' day nine has been correlated with chondrolysis.
146
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Growth Factors

Considerable new bone formation occurs between days
12 and 18. By day 21 an ossicle develops, complete
with hematopoietic marrow lineages (Reddi, 1984).

Soft tissue wound healing and osseous regeneration
are believed to involve an analogous sequence of cellular
events and the cascade of events is largely governed by
locally generated factors that regulate processes leading
to regeneration of damaged tissue. Growth factors stimulate cell replication. Growth factor receptors are intrinsic to all cells capable of replicating. Therefore, growth
factors and their receptors are prevalent in thriving tissue. Several growth factors are chemotactic for cells required for tissue regeneration (Canalis et al., 1988;
Leibovich and Wiseman, 1988). Following injury,
platelet-derived growth factor (PDGF; Canalis et al.,
1988), TGF-'1 (Reddi, 1984) and epidermal growth factor (EGF; Canalis et al., 1988; Davidson et al., 1988)
are released from the alpha granules of degranulating
platelets. The literature suggests that the five growth
factors which have the greatest potential to augment
bone regeneration in vivo include PDGF, TGF-'1, EGF,
insulin-like growth factor-I (IGF-1), and basic fibroblast
growth factor (bFGF; Hauschka 1990). These growth
factors either have been found in bone or are capable of
stimulating bone cells and tissues in a variety of in vitro
and in vivo studies. It is possible that the five growth
factors outlined below may be candidates for use in bone
regeneration materials. Sufficient information is not
available at this time to determine whether they can be
used alone or if they will have to be used in combination
with bone inducing protein to produce optimal bone
regeneration.

Bone Morphogenetic Protein
Although DBM appeared to be promising, the osteoinductive potential of DBM may be limited by the quantity of DBM that can be surgically placed into the recipient bed to produce a therapeutic effect. Optimi1;Altion
and augmentation of osseous induction has been attained
by extracting bone inductive proteins, such as, OG from
DBM (Sampath et al., 1987). OG was isolated by heparin affinity chromatography and preparative gel electrophoresis and the bone inductive activity was localized
to the zone between 30-40 kiloDaltons apparent molecular mass. The amino acid sequence of tryptic peptides
of OG was similar to BMP-3. Recently, BMP-2A,
BMP-2B, and BMP-3 have been cloned and expressed
(Wozney et al., 1988). BMP-2A is referred to as BMP2; whereas BMP-2B is known as BMP-4. BMP-3 has
been designated osteogenin (Luyten et al., 1989). In
addition, a novel gene for osteogenic protein- I (BMP-7)
The
has been cloned (Ozkaynek et al., 1990).
expanding list of novel BMPs now includes BMP-5,
BMP-6 and BMP-7 (Celeste et al., 1990). The amino
acid sequence of BMPs shows homology of the carboxy
terminal quarter domain and is shared by transforming
growth factor-b (TGF-J'j), thereby categorizing the BMPs
as part of the TGF-J1 supergene family.
Dose-response and time-course studies have been
done using highly purified and characterized human recombinant BMP-2 (derived from Chinese hamster ovary
cell line; Wong et al., 1990). In vivo bone induction
was observed following implantation of the recombinant
protein. Using the rat ectopic bone formation assay, implantation of partially purified recombinant human BMP2 up to 115 µgs resulted in cartilage and bone formation
by days 7 and 14, respectively. High doses of the protein induced bone formation as early as five days following implantation and the histological examination of the
newly formed cartilage and bone did not reveal any significant differences when compared to DBM. cDNA
clones encoding human BMP-5, BMP-6, and BMP-7
have been isolated. In addition, the effects of human
recombinant BMP-1, BMP-2 and BMP-3 were examined
on alkaline phosphatase activity, collagen synthesis and
DNA synthesis in cultured osteoblastic cells (3MCT3El). These BMPs were found to stimulate the expres-

PDGF
PDGF is perhaps the most abundant growth factor
in serum, originating from platelet alpha granules. It
exhibits chemotactic activity for monocytes, smooth
muscle cells, and fibroblasts, where the AB and BB
forms are more active than AA homodimer. In mitogenic assays, PDGF AB and BB forms are equipotent,
while the homodimer is almost ineffective. Using bone
organ culture, PDGF was shown to stimulate cell replication, collagen synthesis and non-collagen protein synthesis (Leibovich et al., 1988). PDGF has been shown
to augment fibroblast proliferation needed for the formation of connective tissue, smooth muscle cells and endothelial cells required for neovasculariz.ation (Leibovich
and Wiseman, 1988). The mechanisms of action for
these processes remain obscure. In general, there is
strong evidence that PDGF is a competence factor.
PDGF is synthesized by osteoblasts and is stored in bone

sion of osteoblastic phenotype markers but had no ef-

matrix. PDGF is active in wound healin& and there is

fects on DNA synthesis in the cultured cells. In a recent
study, human recombinant BMP-2 was used with a significant degree of success in mandibular reconstruction
(Toriumi et al. , 1991).

evidence that it stimulates bone repair. PDGF attracts
smooth muscle cells and fibroblasts to the wound sites.
In older rats, this growth factor has been shown to augment demineralized bone matrix-induced heterotopic
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stimulator of resorption, and augments local bone turnover in tissue culture. Work by Beck et al. have shown
that TGF-13 1 promotes calcification within cartilage defects in rabbit ears following the removal of the perichondrium (Beck et al., 1991a). In addition, Beck et al.
have shown that in 12-mm diameter craniotomy defects
in rabbits, 2 mg of human recombinant TGF-13 1 in 3 %
methylcellulose gel causes osteanaphysis by 28 days
post-operation (Beck et al. , 1991b).

cartilage formation which was assessed by production of
mRNA for type II collagen and bone formation, measured by alkaline phosphatase and calcium levels of the
implants (Hauschka, 1990). Interestingly, the effect was
greater in older rats than younger ones, suggesting an
inadequacy of, or decreased response to PDGF in older
animals.

TGF-fJ

TGF-13 (apparent molecular mass of 25 kiloDaltons)
was originally characterized from human platelets,
human placenta, and bovine kidney. It is comprised of
two identical subunits cross-linked by disulfide bonds.
Two cartilage induction factors, CIF-A and CIF-B, now
known as TGF-13 1 and TGF-132 were found to have related amino-terminal sequences. Other factors whose
amino acid sequences place them in the TGF-13 family
include inhibin, the transcript of the decapentaplegic
gene complex in Drosophila, and the BMPs. It is interesting to note that the amino acid sequence of TGF-13 is
almost identical in a variety of species, including man,
mice, chickens, cows, monkeys and pigs (Sporn and
Roberts, 1989). TGF-13 is known for its antiproliferative
effects on cells, particularly epithelial cells, but inhibition is also common for mesenchymal cell such as fibroblasts and endothelial cells. In several cases, the
antiproliferative effects correlate with augmented cellular
differentiation and it has been suggested that the antiproliferative effect appears to operate distal to the receptors for other growth factors. TGF-13 has been shown
to have both stimulatory and inhibitory effects on proliferation of cultured osteoblasts in different studies
(Hauschka, 1990).
TGF-13 is known to be crucial for wound healing.
The growth factor has been shown to augment two processes required for normal healing: collagen formation by
fibroblasts and angiogenesis (Hauschka, 1990). Bone
cells synthesize this growth factor and store it in an inert
form in the extracellular matrix, thus making bone the
most abundant source of TGF-13 in the body. The
growth factor is transformed to its active form under
acidic conditions, such as those produced either during
bone resorption or by macrophages. Active TGF-13 converts mesenchymal cells into cartilage cells. It augments
production of collagen, fibronectin, and plasminogen activating factor in bone cells that are needed for optimum
regeneration of bony tissue. Both TGF-13 1 and TGF-132
appear to act interchangeably in most systems, but a specific role has been demonstrated for TGF-132 in muscle
induction in the embryo. TGF-13 1 is most evident in
focal areas of epithelial-mesenchymal interactions during
periods of morphogenesis and remodeling. TGF-13 appears to be involved in bone remodeling where it augments resorption and formation of PGEi, a powerful

EGF
EGF, a 6.0 kiloDaltons polypeptide, contains 53
amino acid residues and 3 intramolecular cross-links.
Osteoblast-like cells appear to express the EGF receptor,
thereby being candidates for modulation by EGF. Receptors for EGF have been located on other bone cell
types, including a macrophage-like cell and a cell type
similar to undifferentiated stem cells. EGF is mitogenic
for cells of both ectodermal and mesodermal origin (including osteoblasts; Davidson et al., 1988; Hauschka
1990). Using reverse transcriptase polymerase chain reaction technology, it was shown that cultured embryonic
ectomesenchyme of the developing mandible produced
mRNA for EGF in a time-dependent fashion (Snead et
al., 1989). Various effects of EGF in bone organ cultures include mitogenic stimulation of periosteal fibroblasts and osteoblasts, decreased synthesis of type I
collagen and alkaline phosphatase. Effects on osteoblastic cells include augmented DNA synthesis, decreased collagen synthesis, increased PGEi synthesis,
altered intracellular calcium and increased collagenase
and collagenase inhibitor synthesis (Cohen, 1962). EGF
lowers the responsiveness of osteoblastic adenylate cyclase to PTH, similar to the findings for other growth
factors. The ability of EGF to stimulate soft tissue
wound healing is well known. In a recent study it was
used with donor skin graft sites in man where it considerably decreased the healing time (Davidson et al.,
1988).

IGF-1
IGF-1, a 7 .6 kiloDaltons polypeptide consists of 70
residues in a single chain with 3 internal disulfide bonds.
The name for the growth factor was based on its ability
to augment some biochemical reactions controlled by insulin, such as liver glycogen synthesis and bone collagen
synthesis. It is also known as somatomedin C. Skeletal
growth factor was found to be identical to IGF-2, which
is homologous to IGF-1. Biological activities of IGF-1
can be regulated by several known binding proteins.
The growth factor was originally thought to be a systemic growth factor regulated by growth hormone but it is
clear that IGF-1 is produced by a number of tissues. It
has been shown to be produced by isolated osteoblasts,
cultured calvariae and osteoblast-likecells, and cartilage,
148
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Delivery Systems

where IGF-1 regulates metabolism of proteoaminoglycans in a steady-state (Hauschka, 1990). IGF-1 was
shown to stimulate synthesis of DNA, collagen and noncollagen protein in cultured rat calvariae (Canalis,
1980). The growth factor augments cell proliferation
and collagen synthesis in cultured osteoblast-like cells
and in the layer of immature cells adjoining the periosteum and periosteum-free calvariae. Studies using infusion of growth hormone and IGF-1 in rats implicated somatomedin production to play an important role in endochondral bone growth. There is evidence that indicates
that longitudinal bone growth is regulated by growth
hormone via stimulation of IGF-1 production (Hauschk:a,
1990).

The regeneration of bone of the mandibular and craniofacial complex (or of any skeletal tissue) may be possible if a delivery system is constructed having appropriate chronobiologic properties and architectural specifications.
Specifically, the architectural design should
support bone ingrowth (osteoconduction) from host bone
margins. Specifications for osteoconduction must support the progression of angiogenesis and subsequent neovascularization. Therefore, an average pore size should
be approximately 200 - 400 mm (Ohgushi et al., 1990;
mimicking the average haversian system where osteocytes are no greater than 300 mm from the central
haversian canal). In our laboratory, we advocate attaining the maximal pore density possible to optimize cell
ingrowth, neovascularization, and osteoconduction. It
must be remembered that the requirement for strength
from the delivery system does need to be equivalent to
bone. The capacity to maintain spatial orientation of the
bone fracture or bone fragments will be the distinction
of the fixation device, not of the delivery vehicle. In
addition to the architectural requirements, the vehicle
must afford optimum opportunity for cell attachment.
Normal pluripotential cells are anchorage dependent;
therefore, an attachment platform is needed by these
cells before they may be modulated into preosteoblast
phenotypes. Once cells attach to a substratum (the biodegradable carrier), cells must interact with that carrier
to allow for appropriate spatial adaptation leading to
signal transduction and gene expression of type I bone
collagen, alkaline phosphatase, and the polypeptide soup
needed for bone regeneration. Furthermore, the chronobiological dependency of the healing continuum requires
that the appropriate quantity of bone inductive protein
and growth factors are released at a therapeutic dose at
. the proper point(s) in time to push the bone formation
cascade to completion: the regeneration of lost form and
function. The delivery vehicle must be programmed
with the exacting release kinetics calibrated to local
requirements of the osseous tissue to be regenerated.
Mandibular and craniofacial locales do not have the
same vascular supply and functional demands that a long
bone site will have. Consequently, the design for a bone
regenerative material (BRM) must be site-specific. Furthermore, soft tissue prolapse into an ablative wound
must be prevented. In addition to deploying the appropriate payload by dose and time, the delivery vehicle
must occupy the ablative segments long enough to allow
bone regeneration but not so long as to retard that regeneration. Also, the BRM must maintain mass to prevent
soft tissue prolapse.
Applied bone research focused on the development
of alternatives to autografts and allogeneic bank bone

FGF
FGF is found as both an acidic and basic form, representing a family of related growth factors apparently
resulting from gene duplication and evolutionary divergence from a common ancestral protein. The growth
factor is a single chain polypeptide containing 146 amino
acids with apparent molecular weight ranging from 1618 kiloDaltons. Because of its affinity for heparin, it is
also called heparin binding growth factor, type 2
(Davidson et al., 1988). Basic FGF (bFGF) is mitogenic for a variety of cells, including fibroblasts, chondrocytes, osteoblasts, myoblasts, smooth muscle cells,
glial cells and endothelial cells. In addition to its
mitogenic effect, bFGF increases osteocalcin content of
conditioned media, suggesting that bFGF modulates
function of osteoblast-like cells. The growth factor is
synthesized by macrophages, endothelial cells, bone cells
and cultured calvariae from which it is secreted into the
extracellular matrix (Hauschk:a, 1990). It binds loosely
to heparin-sulfate proteoglycans. It has been isolated
from DBM by guanidine extraction followed by heparinsepharose affinity chromatography. The growth factor
has been proposed to be involved in bone remodeling.
When a single injection of 150 ng of bFGF was given to
a subcutaneous wound model, it was as effective as
continuous infusion of 100 ng EGF/day. These data
suggested that bFGF acts as a "competence" factor
(Davidson et al., 1988). An interesting activity of the
factor is its ability to substitute with high degree of
specificity for the morphogenetic action of the ventrovegetal factor in Xenopus development. bFGF augmented angiogenesis when infused into graft sites of mandibular ramus and body in rabbits (~analis, 1980). Increase in concentrations of calcium and PG.Ei in media
have been noted when the growth factor was added to
the culture media of neonatal mouse calvariae. In chondrocytes, interleukin-I -mediated proteinase release can
be greatly augmented by bFGF (Hauschka, 1990).
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can be successful if basic fundamentals of bone regeneration physiology and bone homeostasis are followed.
This paper reviewed several important principles that
could be useful in that quest.
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